Compare American Well Corp (AMWL) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Well Corp vs Becton Dickinson and Co — how do they compare? American Well Corp trades at $12.88 (market cap $220.94M), while Becton Dickinson and Co trades at $181.29 (market cap $49.41B). The key difference: Becton Dickinson and Co is far larger — about 223.6× American Well Corp's market cap, and Becton Dickinson and Co pays a 2.32% dividend while American Well Corp pays none. Which is the better fit depends on your goals.
| AMWL | BDX | |
|---|---|---|
Market Cap | $220.94M | $49.41B |
Sector | Health | Health |
52-Week High | $13.58 | $185.39 |
52-Week Low | $3.78 | $138.62 |
Enterprise Value | $27.98M | $65.51B |
Dividend Yield | — | 2.32% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
